Notably, YAP/TAZ is involved in tamoxifen‐resistant as well as trastuzumab‐resistance in breast cancer, indicating that the survival rate may increase through inhibiting the activity of YAP/TAZ.184, 185. Here, YAP1 is linked to breast carcinoma.